Bellicum planning changes to end clinical hold

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA has outlined criteria required to lift the agency's clinical hold on U.S. trials of adjunct T cell therapy BPX-501. The treatment, which consists of genetically

Read the full 317 word article

User Sign In